Category

IBTA News

IBTA e-News February 2017 released

The IBTA’s monthly e-News has now been released and has been emailed to all subscribers. Some of the highlights from the February issue include: Brain Tumour Awareness Month in the UK, the creation of a surgical probe the size of a human hair, the finding that drugs derived from chemicals in the cannabis plant may have a role in brain tumour palliative care…

Read More

The IBTA at SNO 2016

The IBTA was delighted to exhibit at the 21st Society for Neuro-Oncology Annual Scientific Meeting, held at the Fairmont Princess Hotel in Scottsdale, Arizona, on 18-22 November 2016.
This year’s meeting was the largest ever, with over 2,350 attendees (200 more than 2015) and 1,024 abstracts submitted (100 more than last year). The IBTA was represented at the conference by Chair Kathy Oliver (UK) and Senior Advisor Chris Tse (New Zealand)…

Read More

IBTA e-News August 2016 released

The IBTA’s monthly e-News has now been released and has been emailed to all subscribers. Some of the highlights from the August issue include: The 10th International Brain Tumour Awareness Week is fast approaching and will be held from Saturday, 22nd October to Saturday, 29th October inclusive. No matter where you live…

Read More

IBTA e-News July 2016 released

[25 July 2016] The IBTA's monthly e-News has now been released and has been emailed to all subscribers.

Some of the highlights from the July issue include:

  • A research study has found that gross total resection (complete tumour removal) extends survival in glioblastoma patients, compared to subtotal (incomplete) resection. A separate study on mice has found that glioma tumour cells left in the brain after removal surgery grow more aggressively than the original tumour.
  • Research published in the British Journal of Cancer has made the unexpected finding that high blood sugar levels are linked to a reduced risk of meningioma.
  • Experiments on mice have shown that glioma cells use fats (fatty acids) as their primary fuel source. It had been previously thought that glucose was the main fuel source for tumour cells. The authors suggest that previous research did not reflect how tumour cells actually function within the brain.
  • Novocure's second generation Optune, a Tumor Treating Fields (TTFields) device, has been approved for use in the United States by the US Food and Drug Administration (FDA).
  • A new version of the UK Cancer Drugs Fund (CDF) comes into effect on 29thJuly 2016. a coalition of 15 leading UK cancer charities previously expressed “deep concern” that the new CDF will ultimately reduce the number of patients receiving vital treatments.
  • The FDA has granted Rare Pediatric Disease Designation for AbbVie’s ABT-414 - an antibody combined with a drug that targets epidermal growth factor receptor (EGFR) - for the treatment of paediatric patients with EGFR-amplified diffuse intrinsic pontine glioma (DIPG).
  • You can read the IBTA e-News July edition online here

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News by registering here.

To see an archive of existing e-News issues, click here.

IBTA e-News June 2016 released

[1 July 2016] The IBTA's monthly e-News has now been released and has been emailed to all subscribers.

Some of the highlights from the June issue include:

  • "We've reached an inflection point in our fight against cancer," announced US Vice President Joe Biden, whose son died of a brain tumour, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO 2016), held in Chicago in June
  • Two separate studies find out that elderly glioblastoma patients live longer with combined chemotherapy and radiation therapy
  • A clinical trial has shown that a technology that uses microbubble injections combined with an implanted ultrasound device can disrupt the blood-brain barrier in glioblastoma patients, allowing chemotherapy drugs to enter the tumour
  • A research study points to a link between dopamine and glioblastoma growth
  • Results from a phase 1 trial of Toca 511 and Toca FC, a modified virus that carries a gene into tumour cells combined with a drug that targets the modified tumour cells, have shown that patients with recurrent glioblastoma have extended survival
  • Analysis of blood samples from 110 people who went on to develop glioblastoma has indicated that high levels of vitamin E could be a risk factor
  • Clinical trials for immunotherapy in childhood DIPG tumours, and for young people and children with ependymoma are now recruiting patients
  • An observational study has suggested that people with higher levels of education and greater earnings have a greater risk of being diagnosed with a brain tumour
  • You can read the IBTA e-News June edition online here

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News by registering here.

To see an archive of existing e-News issues, click here.

Subscribe to IBTA's e-News!